Neuronal Effects of Exercise in Schizophrenia
Part of paid clinical trials in Aurora, Colorado.
- Sponsor
- University of Colorado, Denver
- Study ID
- NCT02455193
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Exercise — BEHAVIORAL
- Diet — BEHAVIORAL
Study Details
This study plans to learn more about how common drugs prescribed to individuals with schizophrenia contribute to weight gain, as well as how exercise and diet impact appetite and the brain's response to food. In this study, the investigators will be evaluating how participants' brains respond to food images as well as asking questions about their food preferences and intake and clinical symptoms. The investigators may also ask participants to complete an exercise or diet intervention to see how this changes brain responses or food preferences.
Key Dates
- Start date
- Aug 31, 2014
- Status verified
- Apr 2025
- Primary completion
- Sep 30, 2025
- Completion
- Sep 30, 2025
Study Design
- Enrollment
- 140 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Experimental: Exercise intervention10 weeks of a moderate exercise intervention
- Active Comparator: Diet intervention10 weeks of a diet intervention
Primary Outcome Measure
Neuronal response to visual food cues [ Time Frame: 14 weeks ]
Central Contacts
- Kristina T Legget, Ph.D.303-724-5809
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 |
Find similar trials in Aurora, CO
By condition
By specialty
By research site
Related Studies
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderPHASE3 · Recruiting · Alkermes, Inc. · Dothan, Alabama
- Safety and Tolerability of Open-Labeled Iloperidone in AdolescentsPHASE4 · Recruiting · Vanda Pharmaceuticals · Little Rock, Arkansas
- Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderPHASE3 · Recruiting · Intra-Cellular Therapies, Inc. · Phoenix, Arizona
- Zyprexa® Relprevv™ Patient Care ProgramEnrolling By Invitation · Eli Lilly and Company · Blue Bell, Pennsylvania